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P001-A: Short-term pregnancy hormone treatment
on N-Methyl-N-nitrosourea-induced mammary
carcinogenesis in relation to serum fatty acid
composition
Airo Tsubura, Yen-Chen Lai, Katsuhiko Yoshizawa,
Takashi Yuri, Norihisa Uehara and Ayako Kawanaka,
Tomo Sasaki
Department of Pathology, Kansai Medical University, Moriguchi,
Osaka 570-8506, Japan
Short-term estrogen and progesterone treatment (STEPT) mimics
the pregnancy hormone milieu. This study compared the development of
N-methyl-N-nitrosourea (MNU)-induced mammary cancer in female
Lewis rats that received STEPT in early or later life. Rats in Groups 1 and
2 received a single intraperitoneal injection of 50 mg/kg MNU at
4 weeks old. Pellets containing 0.5 mg 17b-estradiol and 32.5 mg pro-
gesterone (EP) were subcutaneously implanted in rats in Group 1 during
6–9 weeks old. Rats in Groups 3 and 4 received 50 mg/kg MNU at
22 weeks old and again at 23 weeks old.
EP pellets were implanted in rats in Group 3 during 24–27 weeks
old. At the time of EP removal and 8 weeks afterward, 4 randomly
selected rats in each group were sacrificed for blood sampling. The
fatty acid composition of serum phospholipids was measured by
capillary gas chromatography. The remaining rats were sacrificed
when they developed mammary tumours C1 cm in diameter or at the
termination of the experiment, which was at 18 weeks old for Groups
1 and 2 and at 64 weeks old for Groups 3 and 4. Mammary cancer
was histologically confirmed. Group 1 had a significantly suppressed
incidence of mammary cancer compared to Group 2 (7% vs. 90%),
whereas the cancer incidence in Group 3 was similar to that of Group
4 (50% vs. 56%).
Rats in Group 1 had significantly smaller n-6/n-3 polyunsaturated
fatty acid (PUFA) ratios and higher levels of docosahexaenoic acid
(DHA) than those in Group 2 at the time of EP removal but not
8 weeks after EP removal. Neither the PUFA ratios nor the DHA
levels differed between Groups 3 and 4 at any time. These data
suggest that the age at which STEPT is administered is important,
since its mammary cancer-suppressing potential was lost in aged
animals. DHA and the n-6/n-3 PUFA ratio may play a crucial role in
mammary cancer suppression by STEPT.
P002-B: Identification of mammary gland
development genes in mouse by ENU mutagenesis
Prudence Stanford1, Wendy Au1, Victoria Adams2,
Belinda Whittle2, Cara Evans1, Alice Boulghourjian1,
Matthew Naylor1, Samantha Oakes1, Ed Bertram2,
Christopher Goodnow2, Moira O’Bryan3
and Christopher Ormandy1
1Cancer Program, Garvan Institute of Medical Research, NSW,
Australia, 2Australian Phenomics Facility, Australian National
University, ACT, Australia, 3Monash University, VIC, Australia
Rationale: The use of N-ethyl-N-nitrosourea (ENU) to induce mutations
in mice has been a successful approach in identifying new gene func-
tions, by correlating phenotypic effects with the induced genetic altera-
tions. We were interested in using this approach to identify genes that
regulate mammary gland development and lactation. Since genes that
regulate normal mammary development are often associated with
breast tumorigenesis, this project may provide new therapeutic targets
for breast cancer.
Aims: To identify genes that regulates mammary gland develop-
ment and lactation.
Methods: Lactational behaviour of mice derived from ENU-
treated mice was determined by monitoring pup weight, milk spot and
survival. Mammary glands were examined by whole mount and H&E
stainings. Gene expressions and milk composition were determined
by quantitative RT–PCR, immunohistochemistry and Western blot-
ting. Cell proliferation and apoptosis were assessed by BrdU and
cleaved-Caspase 3 stainings, respectively. Gene mutations were
identified using PCR genotyping of polymorphic markers, followed
by Next Generation sequencing. The expression pattern of the iden-
tified gene during mammary gland development was examined by
both quantitative RT–PCR and immunohistochemistry.
Results: We identified a line of mice (Jersey) exhibiting inheritable
dominant lactation failure. Ductal branching during pregnancy was
normal. Alveolar development was reduced during late pregnancy and
lactation. Mammary epithelial cell proliferation in early pregnancy is
significantly less in Jersey glands, and is accompanied by increased
apoptosis post-partum. Although milk was present in the Jersey
glands, the alveolar lumens do not expand like the wild-type lactating
glands, suggesting a reduction in milk volume. In addition, expression
of beta-casein and whey acid protein in the milk are also decreased.
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Two closely linked ENU-induced mutations were found in the
affected Jersey mice. One was non-coding, and mice carrying null
mutation of this gene showed normal lactation. The second mutation
caused an amino acid change in a functional domain of the protein.
The corresponding wild-type gene was found to be expressed in
mammary epithelial cells at different stages development. We are
currently investigating the potential mechanism of this mutation that
results in the lactation phenotype.
Conclusion: We had identified a gene mutation which affects the
proliferation, differentiation and apoptosis of the mammary epithe-
lium at different stages of development.
P003-A: Identification of PUMA as an oestrogen target
gene that mediates the apoptotic response to Tamoxifen
in human breast cancer cells and predicts patient
outcome in breast cancer
Caroline G. Roberts1, Ewan K.A. Millar1,2, Sandra A.
O’Toole1,3, Catriona M. McNeil1,4, Gillian M. Lehrbach1,
Mark Pinese1, Elizabeth A. Musgrove1,3, Robert L. Sutherland1,3
and Alison J. Butt1,3
1Cancer Research Program, Garvan Institute of Medical Research,
Darlinghurst, New South Wales, Australia, 2Dept of Anatomical
Pathology, South Eastern Area Laboratory Service, St George
Hospital, Kogarah, NSW, Australia, 3St. Vincent’s Clinical School,
Faculty of Medicine, University of New South Wales, Australia,
4Department of Medical Oncology, Westmead Hospital, Westmead,
New South Wales, Australia
Recognition of the pivotal role of oestrogen in the aetiology of breast
cancer has led to the development of antioestrogens (AE) such as
tamoxifen (TAM) as effective therapies for the treatment and pre-
vention of this disease. However, despite their widespread clinical
efficacy, response to AEs is often short-lived, and acquired or innate
therapeutic resistance remains a major obstacle in the successful
treatment of breast cancer. Thus, delineating the intracellular path-
ways that mediate the cellular response to oestrogen could potentially
lead to new, more effective approaches to the treatment of breast
cancer, particularly endocrine-resistant disease.
We have identified the BCL-2 homology 3 (BH3)-only, pro-
apoptotic regulator, PUMA (p53 upregulated modulator of apoptosis)
as an oestrogen target gene that is acutely downregulated (within 4 h)
in response to estradiol (10 nM) in the human breast cancer cell lines,
MCF-7 and T-47D. Although PUMA has an established role as a p53-
upregulated gene and essential mediator of p53-dependent apoptosis,
oestrogen’s regulation of PUMA occurs independently of the p53
status of the cells. Furthermore, maintenance of this transcriptional
effect in the presence of cycloheximide supports the concept that
PUMA is a primary target of ERa in breast cancer cells.
PUMA is transcriptionally upregulated in T-47D and MCF-7 cells
following treatment with TAM (7.5 lM; within 8 h), and knock down
of PUMA expression in these cells with specific siRNA significantly
attenuates the apoptotic response to TAM compared to non-targeting
siRNA controls (p \ 0.05). A publically available gene expression
data set was analysed to identify relationships between PUMA mRNA
expression and breast cancer patient outcome. PUMA protein
expression was assessed using immunohistochemistry in 292 patients
with invasive ductal carcinoma, and correlated with clinicopatho-
logical variables and disease outcome. Results showed that low
PUMA mRNA and protein expression in breast carcinomas was
significantly associated with breast cancer-specific death (P = 0.0014
and P = 0.0115, respectively).
These findings suggest that the dysregulation of apoptotic sig-
naling pathways such as those executed via PUMA, can significantly
impact on both the progression and therapeutic responsiveness of
breast cancer. Moreover, they provide a convincing rationale for
exploring new therapeutic approaches involving endocrine and non-
endocrine therapies that target apoptotic pathways as an effective
strategy for tackling endocrine refractory disease.
P004-B: Progesterone and Elf5 in mammary gland
development
Heather J. Lee1, Wendy Au1, Cara J. Evans1,
Alice Boulghourjian1, John P. Lydon2 and Chris J. Ormandy1
1Cancer Research Program, Garvan Institute of Medical Research,
Sydney NSW Australia, 2Department of Molecular and Cellular
Biology, Baylor College of Medicine, Houston Texas USA
Elf5 is a key transcription factor that specifies alveolar cell fate in the
mammary gland during pregnancy [1]. The ability of Elf5 to rescue
the failed development of prolactin (PRL) receptor null mammary
glands has established a major role for Elf5 in mediating PRL
action during pregnancy [2]. We have recently reported that Elf5 is
also regulated by progesterone (P) in cell lines and mice [3], raising
the possibility that Elf5 co-ordinates both P and PRL actions. The
aims of this study were to determine whether Elf5 mediates P action,
and to investigate how P and Elf5 co-operate during mammary
development.
Elf5 transgenic mice were crossed with PRLacZKI animals to
allow induction of Elf5 in mammary glands null for PR, and trans-
plantation studies were used to assess the development of these glands
during pregnancy. To study the combined effects of Elf5 and P,
Elf5 transgenic mice were implanted with a sub-cutaneous slow-
release P pellet and Elf5 expression was induced by doxycycline
administration.
Induction of Elf5 did not rescue the failed development of PR null
transplants, indicating that Elf5 is not primarily responsible for P
action during pregnancy. However, Elf5 and P had additive effects on
endpoints of mammary gland differentiation that may be reflected at
the level of luminal progenitor cells. Most notably, in the presence of
P, Elf5 promoted the formation of clusters of polarised alveolar buds.
This phenotype resembles that achieved by over-expression of
RANKL [4], a mediator of P’s paracrine actions. We also report that
PR and Elf5 are expressed in neighbouring mammary cells, consistent
with the idea that P induces Elf5 expression via a paracrine mecha-
nism. In conclusion, Elf5 co-operates with P to promote alveolar bud
formation. Further work will investigate whether RANKL mediates P
induction of Elf5 expression.
[1] Oakes et al. (2008). ‘‘The Ets transcription factor Elf5 specifies
mammary alveolar cell fate.’’ Genes Dev 22(5): 581–586.
[2] Hilton et al. (2010). ‘‘The anti-proliferative effects of
progestins in T47D breast cancer cells are tempered by progestin-
induction of the ets transcription factor Elf5’’. Molecular Endocri-
nology 24(7): 1380–1392.
[3] Harris et al. (2006). ‘‘Socs2 and Elf5 mediate prolactin-
induced mammary gland development.’’ Molecular Endocrinology
20(5): 1177–1187.
[4] Fernandez-Valdivia et al. (2009). ‘‘The RANKL signaling axis
is sufficient to elicit ductal side-branching and alveologenesis in the
mammary gland of the virgin mouse.’’ Dev Biol 328(1): 127–139.
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P005-A: Defining the role of the ETS transcription
factor Elf5 in the breast cancer phenotype
David Gallego-Ortega, Maria Kalyuga, Heather J. Lee,
Cara J. Evans and Christopher J. Ormandy
Cancer Research Program, Garvan Institute of Medical Research.
Sydney NSW. Australia
Elf5 (e74-like factor 5) is a member of the ETS family of transcription
factors. This family is involved in the regulation of cellular differenti-
ation, development, cell cycle control, proliferation, survival and
tumorigenesis. Elf5 mediates prolactin action; high Elf5 expression is
essential for lactation, specifying differentiation of the CD61+ mam-
mary progenitor cell population to form the secretory cell lineage.
Comparison of gene expression profiles between patient-matched
breast tumour and normal samples revealed that Elf5 is one of the most
consistently down-regulated genes during carcinogenesis, with a large
loss of Elf5 expression observed in luminal cancers and more moderate
loss by the basal subtype. Thus higher Elf5 expression is associated with
high-grade tumours, lymphocytic infiltration and with BRCA1 muta-
tion, reflecting the basal-luminal differences in these features. The
recent identification of the CD61+ progenitor cell as the source of
BRCA1 tumours, together with higher Elf5 expression in Basal cancers,
suggest the CD61+ progenitor cell as the origin of basal breast cancers
and that Elf5 may be a key driver of the basal phenotype.
In the present study, we have investigated the effect of Elf5 on
breast cancer cell phenotype and in mouse models of carcinogenesis.
For that purpose, we have developed a doxycycline (Dox) inducible
model of Elf5 expression in basal and luminal human breast cancer
cells. Forced expression of Elf5 to levels seen in normal epithelium
inhibited cell proliferation both in vitro and in vivo, via mechanisms
involving cell cycle and survival parameters. Elf5 over-expressing
cells displayed a reduction in the number of colonies in soft agar,
indicating reduced anchorage-independent growth. In vivo studies
reveal that Elf5 over-expression prevented tumour growth in subcu-
taneous xenografts of breast cancer cell lines in athymic nude mice.
Using the intraductal cell xenotransplantation model, which provides
a more appropriate niche for the tumour cells, we observed a reduc-
tion in tumour formation by the Elf5 over-expressing breast cancer
cells. Furthermore, using the polyoma middle T oncoprotein (PyMT)
mouse model, we have created a triple transgenic mouse carrying
PyMT and a Tet-On MTB-promoter Elf5 construction. Although
overall tumor incidence and growth rate are similar in Elf5 expressing
mice compared to controls, Elf5 expression shows heterogeneous
patterns of intratumoral expression and immuno-fluorescent studies
using BrDU reveal a very marked reduction in the proliferation in
areas of the tumour with high Elf5 expression. Efficient carcinogen-
esis requires reduced expression of the Elf5 transgene.
Thus forced re-expression of Elf5 to levels seen in normal breast
epithelium stops luminal and basal breast cancer cell proliferation both
in vitro and in vivo as well as the tumour formation of xenografts in
immuno-compromised mice. This provides the first study of the in vivo
effect of Elf5 over-expression in breast carcinogenesis and indicates
that therapeutic strategies designed to mimic the effects of Elf5 re
expression may prove efficacious for the treatment of breast cancer.
P006-B: Proteomics of invasive and metastatic
human breast carcinoma
Kah Wai Lin and Serhiy Souchelnytskyi
Karolinska Biomics Center, Karolinska Institutet, Karolinska
University Hospital, SE-17176 Solna, Stockholm, Sweden
Introduction: Metastasis includes loss of cellular adhesion, invasion
into extracellular matrix, entry into circulation, exit into new tissue
and colonization of a distant site. The primary objective of this study is
to establish an isogenic model of invasiveness and study mechanism of
cancer invasion by proteomics and systems biology approaches.
Experimental Procedures: By selecting the cells invaded into
gelatin, highly invasive clones of MCF-7 cells were obtained for
further study. 2D gels of parental MCF-7 cells, invasive MCF-7c46
cells and invasive, metastatic MDA-MB-231 cells were generated and
differently expressed proteins were identified by mass spectrometry.
Systemic analyses were performed, included functional clustering,
pathway and network analysis. Networks formed by identified inva-
siveness-related proteins were used for selection of proteins for
further study.
Selected proteins were validated by immunoblotting with specific
antibodies. To manipulate levels of selected proteins, overexpression
and siRNA knockdown experiments were performed, and cell inva-
siveness, proliferation and apoptosis were measured.
Summary of data. We isolated a highly invasive clone of MCF-7
cells, MCF-7c46. Invasion assay showed that their invasiveness
across matrigel barrier is 10-fold higher than their parental cells. The
subsets of differentially expressed proteins from 2D gel were defined
to extract invasiveness-specific proteins, i.e. MCF-7 v.s. MCF7c46
(non-invasive v.s. invasive), MCF-7 v.s. MDA-MB-231 (non-invasive
v.s. invasive, metastatic), and MCF-7c46 v.s. MDA-MB-231 (inva-
sive v.s. invasive, metastatic). By functionally analysis, all three
subsets of proteome profile showed significant similarity in affected
functional domains, but ECM organization and biogenesis were more
represented in non-invasive v.s. invasive subset, i.e. MCF-7 v.s.
MCF7/46, and MCF-7 v.s. MDA-MB-231. Systemic analysis of
invasive-specific network, which is a overlapped network of the
subsets MCF-7 v.s. MCF7c46, and MCF-7 v.s. MDA-MB-231,
revealed several major hubs, e.g. TGFbeta, EGF, VEGF, IGF,
NFkabbaB and HNF. The network analysis showed relations between
these regulatory processes.
Subsequently, the key regulators for breast carcinoma invasion
were selected for validation and functional and study.
Conclusions: New isogenic model of invasiveness of human breast
epithelial cells has been generated. Major hubs in the invasiveness-
specific network have been identified. They include TGFbeta, EGF,
VEGF, IGF, NFkabbaB and HNF signaling mechanisms in defined
relations, e.g. these mechanisms are involved in regulation of inva-
siveness in a defined order and hierarchy. Network analysis suggested
that BRMS1 is a key regulator of breast carcinoma invasiveness and
its regulatory mechanism is currently under investigation.
P007-A: Tamoxifen-induced epigenetic silencing
of oestrogen-regulated tumour suppressor genes
as a novel concept in anti-hormone resistant
breast cancer
Andrew Stone1,3, Julia MW Gee1, Lynne Farrow1,
Richard A McClelland1, Heidi Fiegl2, Carol Dutkowski1
and Robert I. Nicholson1
1Tenovus Centre for Cancer Research, Welsh School of Pharmacy,
Cardiff, UK, 2Austria Tyrolean Cancer Research Institute, Medical
University of Innsbruck, Austria, 3Garvan Institute of Medical
Research, Sydney, NSW, Australia
Previous studies at the Tenovus Centre have demonstrated that the
development of tamoxifen-resistance in vitro can be attributed to
aberrant growth-factor receptor signalling, which facilitates advanced
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aggressive behaviours in breast cancer cells such as increased pro-
liferation. The aim of the present study was to determine how these
undesirable features of resistant cells were affected following with-
drawal from tamoxifen.
Interestingly, in MCF-7-derived tamoxifen-resistant cell sub-lines
that had been withdrawn from tamoxifen for up to 6 months, the
increased rate of proliferation was sustained despite the reduced
expression of epidermal growth factor receptor (EGFR) and reduced
sensitivity to EGFR signalling inhibition. Here, evidence is presented
to suggest that the accelerated rate of proliferation was in part
maintained by epigenetically modified oestrogen responsive tumour
suppressor genes, silenced following long-term tamoxifen exposure.
Using quantitative PCR, immunocytochemistry and MethyLight
technology, proof-of-principle studies demonstrated the methylated
status of promoter sequences for the prototypic oestrogen-responsive
genes, trefoil factor-1 (pS2) and progesterone receptor in our resistant
cell model. The ‘silent state’ of these promoters was reversed using a
combination of the de-methylation agent 5-Azacytidine (5-Aza) and
oestradiol (E2). Surprisingly, 5-Aza treatment enabled E2, a modest
mitogen in the absence of this agent, to become a significant inhibitor
of resistant cell growth. This was apparent over physiological levels of
E2 (1 9 10-9 M–1 9 10-7 M), with the maximal dose of E2 causing
a 50% reduction in the number of cells following 7 days culture
compared to non-E2 (+5-Aza) treated cells (p \ 0.001). In contrast,
cells cultured in the absence of 5-Aza showed a 40% increase in cell
number with E2 at 1 9 10-7 M (compared to non-E2/non-5-Aza
treated control cells) (p \ 0.001). Further analysis showed that the
addition of tamoxifen (1 9 10-7 M) to cells cultured with 5-Aza and
E2 reversed this growth suppression; hence it could be argued that
the co-addition of tamoxifen suppressed the genes reactivated by
5-Aza/E2 co-treatment that are responsible for this phenomenon.
Subsequent microarray analysis revealed a cohort of genes whose
ontology indicated tumour suppressor/pro-apoptotic function, includ-
ing Growth Differentiation Factor-15 (a TGFb-superfamily member
reported to lie down-stream of p53), as being methylated during long-
term tamoxifen exposure. Such genes were re-expressed when cells
were treated with 5-Aza + E2 in parallel with growth inhibitory effects.
Thus, the data in this study provides evidence to support a novel
concept that directly links anti-hormone-induced hypermethylation of
oestrogen-regulated tumour suppressor gene promoters to acquired
anti-hormone resistant cell growth, and highlights a previously unrec-
ognised therapeutic opportunity in tamoxifen-resistant breast cancer.
The identification of genes associated with this phenomenon could
provide further insight into the mechanisms that contribute to acquired
tamoxifen-resistant cell growth, while their profiling could also
potentially have significant predictive response value. Furthermore, the
restoration of their expression or function on an individual basis may
ultimately be valuable in improving treatment of tamoxifen resistant
breast cancer and may be more desirable than epigenetic manipulation,
which may have a broader genomic impact in cancer.
P008-B: Pathology and clinical impact of Chromosome
17q12-q21.2 genes copy number amplification
in HER2 positive breast cancers
Pierre-Jean Lamy1, Fre´de´ric Fina2, Caroline Mollevi3, Anne-Claire
Servanton1, Pierre-Marie Martin2, L’Houcine Ouafik2, 5 and William
Jacot4
1Lab. de Biologie Spe´cialise´e et d’Oncoge´ne´tique, CRLC Val
d’Aurelle-Paul Lamarque, Montpellier, F-34298 France, 2Laboratoire
de Transfert d’Oncologie Biologie, Assistance Publique – Hoˆpitaux
de Marseille, F-13916 France, 3Unite´ de Biostatistique CRLC Val
d’Aurelle-Paul Lamarque, Montpellier, F-34298 France, 4Service
d’Oncologie Me´dicale, CRLC Val d’Aurelle-Paul Lamarque,
Montpellier, F-34298 France, 5UMR 911 CRO2 : Centre de
Recherche en Oncologie biologique et Oncopharmacologie,
Marseille, F-13344, France
It has been described that amplifications in the chromosome 17 (ch17)
could affect different genes implicated in cancer development. The
aim of the study was to determine, by quantitative PCR (qPCR), the
amplification level of different genes located on ch17q12-21in HER2
positive breast cancers.
We determined GRB7, TOP2A, THRA, IGFBP4, CCR7, KRT20,
KRT19 and GAS gene copy numbers by quantitative PCR in 86
HER2 amplified and 40 HER2 negative breast tumors. Patients were
included between 2002 and 2006 (median follow-up = 55 months).
They received radiotherapy (100%), anthracycline based regimen
(79%), Herceptin (23%) and hormonotherapy (40%) as adjuvant
therapy according to therapeutic standard used at the time of surgery.
qPCR reactions were performed on a Rotorgene 6000 (Qiagen) using
Absolute Blue QPCR SYBR Green Mix (ref AB-4167, ThermoFisher
Scientific). Amplification levels were normalized with the somato-
statin receptor type II (SSTR2) gene Quantification of SSTR2 was
also normalized with GAPDH and ACBT in order to detect SSTR2
amplification. The quantification was achieved by constructing a
standard curve from serial dilutions of normal genomic DNA (ref 11
691 112 001, Roche, France). Gene amplification was defined by a
ration target gene/reference [ 2.
We confirm that GRB7, TOP2A, THRA, IGFBP4, CCR7, KRT20,
KRT19 and GAS amplification occurs only in patients with HER2-
amplified breast tumor. Gene amplification occurs in 100% for GRB7,
55% for THRA, 23% for TOP2A, 19.5% for IGFBP4, 18.4% for
CCR7, 13.8% for KRT20, 11.5% for KRT19, and 6.9% for GAS. We
show that HER2 presents the highest value of amplification and that
amplification frequency of a gene decrease with the distance from
HER2. The amplification level of HER2 is not correlated with TOP2A
amplification’s levels (rho = 0.11) nor with other genes amplification
levels. Gene amplifications are not correlated with T and SBR.
TOP2A, IGFBP4, KRT20 and KRT19 amplification are statistically
significantly associated with node positive breast cancers (p = 0.077,
0.072, 0.001 and 0.019 respectively).
The HER 2 amplicon do not include GRB7, TOP2A, THRA,
IGFBP4, CCR7, KRT19, KRT20 and GAS. It leads to increased gene
copy number alterations in Chr17q 12-21 that could be related with an
invasive breast cancer profile.
P009-A: Functional significance of TRIM22
in breast cancer
Yang Sun1, Gayathri Sivaramakrishnan1, Gay Hui Ho2,
Koong Heng Nung2 and Valerie Lin Chun Ling1
1School of Biological Sciences, Nanyang Technological University,
60 Nanyang Drive, Singapore 637551, 2Department of Surgical
Oncology, Singapore National Cancer Centre
Tripartite motif-containing 22 (TRIM22) is a member of the TRIM
protein family, characterized by the presence of RBCC motif. It is
inducible by both type I and type II interferons (IFNs) and possesses
antiviral activity against viruses such as Human Immunodeficiency
Virus. It has been identified to be an E3 ubiquitin ligase and a down-
stream target gene of p53. To characterize the function of TRIM22,
we studied the response of TRIM22 to apoptosis inducing drugs.
We showed that TRIM22 expression is induced during cell cycle arrest
in a p53-dependent manner. In addition, we have demonstrated that
68 HUGO J (2010) 4:65–77
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TRIM22 nuclear level increased drastically after IFN-b and mitomycin
C treatment, suggesting that nucleus is the possible site of action for
TRIM22. Western blotting analysis performed on a panel of mammary
epithelial cell lines (3 non-malignant mammary epithelial cell lines and
11 breast cancer cell lines) revealed that TRIM22 expression is high in
non-malignant mammary epithelial cells but hugely downregulated in
malignant breast cancer cell lines. Similar result was obtained when we
examined the TRIM22 protein expression in 63 pairs of human breast
tumor tissue and the adjacent normal tissue. We found the level of
TRIM22 protein is higher in the adjacent normal tissue than the tumor
tissue. These results suggest possible growth inhibitory role of
TRIM22 and its association with breast cancer development.
P010-B: Generation and characterization
of Tetratricopeptide repeat domain 9A knockout mice
Smeeta Shrestha, Xue Ming Dong, Yang Sun,
Petra Kraus, Thomas Lufkin and Valerie Lin
Nanyang Technological University
Tetratricopeptide repeat domain 9A (TTC9A) was originally cloned
from a cDNA library of the brain. It was later found to be drastically
induced by progesterone in breast cancer cells and this induction is
associated with growth-inhibitory effect of progesterone. TTC9A was
also found to be significantly over-expressed in breast cancer tissues as
compared to the adjacent normal tissues. However, information on its
regulation of expression is limited and its function is not clear. To
investigate further the function of TTC9A in mammary development
and mammary carcinogenesis, we have generated mice with deletion of
TTC9A gene using gene targeting to replace exon 1 with neomycin
cassette. Despite the dynamic expression of TTC9A in the developing
mammary gland, nervous system, and other organs, TTC9A-deficient
mice are viable, fertile, and appear to be normal. This report describes
the characterization of mammary and brain development in TTC9A
knockout mice that will shed light to the role of this gene in
development.
P011-A: Splice variant profiling of tamoxifen sensitive
and resistance breast cancer
*US Khoo1, LD Zhang1, YC Ip1, YN Cheung1,
SU Wong1, WH Tsang2 and YK Chan1
1Department of Pathology, 2Department of Clinical Oncology,
Li Ka Shing Faculty of Medicine, University of Hong Kong,
Hong Kong, China
Tamoxifen is a selective estrogen receptor modulator (SERM) widely
used to treat estrogen receptor (ER) positive breast cancers. However
many patients eventually acquire resistance and relapse. Gene expres-
sion profiling studies have identified gene profiles that could better
classify cancer subtypes, predict cancer prognosis or characterize
tamoxifen responsiveness, but with little concordance between the
genes identified. This may partly be due to pre-mRNA alternatively
spliced variants that are not discriminated in conventional microarrays.
The purpose of this study was to identify alternatively spliced variants
that contribute to tamoxifen resistance in breast cancer.
SpliceArrayTM profiling (ExonHit Therapeutics, Inc.) of 417 breast
cancer-related genes was performed in a panel of breast cancer cell
lines. Splice variants that were differentially expressed between parental
tamoxifen-sensitive (TamS) and derived tamoxifen-resistant (TamR)
cell lines were identified and validated by real time-quantitative PCR.
Splice variant BQ323636.1 of NCOR2 (Nuclear receptor co-repressor
2) was successfully validated in cell lines and clinical samples. In presence
of tamoxifen, the mRNA expression level ratio of variant (BQ323636.1)
versus wild type form (NM_006312.2) was significantly higher in derived
TamR cell line AK47 compared to its parental TamS cell line ZR75-1. In
25 Chinese breast cancer patient RNA samples, the ratio positively cor-
related with metastasis.
NCOR2 is a component of the histone deacetylase-containing
protein complex. It is recruited by tamoxifen to repress the tran-
scription activation activity of ERa. BQ323636.1 variant has exon 11
skipped, resulting in early termination of the protein product. Only the
first repression domain at the N-terminal is retained while 3 repres-
sion domains and 2 nuclear receptor-interacting domains are lost,
indicating its disability of binding to nuclear receptors. Thus, this
variant may hinder the repression on ERa transcription activation
activity by competing with its wild type in binding with other protein
partners in the HDAC complex, hindering its recruitment to the target
gene promoter and modulating the antagonist effect of tamoxifen.
Functional studies are being performed to confirm this possible
mechanism, which may serve as a potential therapeutic target to
overcome acquired tamoxifen resistance in breast cancer.
P012-B: Cyclin E2 is expressed in the S phase of cancer
cells and increases genomic instability
C. Elizabeth Caldon, C. Marcelo Sergio, Robert L. Sutherland,
and Elizabeth A. Musgrove
Cancer Research Program, Garvan Institute of Medical Research,
Sydney, New South Wales, Australia
Cyclin E1 is dysregulated in cancer and associated with poor patient
outcome, supporting a causative role in tumorigenesis. High expres-
sion of cyclin E1 increases proliferation, while dysregulation of
periodic expression increases genomic instability. Cyclin E1 is reg-
ulated via periodic expression and degradation: expression peaks at
the G1/S phase transition, and it is then rapidly degraded during
S phase after recognition by the SCF(Fbw7) ubiquitin ligase. The
closely related protein, cyclin E2, has been presumed to be redundant
with cyclin E1. We show that cyclin E1 and E2 are expressed in
distinct subpopulations of cancer cells, due to a failure to co-ordi-
nately degrade the two proteins. Cyclin E2 protein expression was
maintained during S phase while cyclin E1 expression decreased over
the same period. This is likely due to failed targeting of cyclin E2 by
Fbw7, as the inactivation or depletion of Fbw7 led only to significant
changes in the stability of cyclin E1, but not cyclin E2. Cyclin E1 and
E2 were concordantly expressed and regulated in normal cell lines,
suggesting that cyclin E2 regulation is specifically perturbed in cancer
cells.
Expression of cyclin E1 during S phase leads to genomic insta-
bility. Since we observed S phase expression of cyclin E2, we assayed
the effect of overexpression of cyclin E1 and E2 on the induction of
micronuclei, a marker of genomic instability. Cyclin E2 induced
micronucleation at a greater rate than cyclin E1. These data imply that
cyclin E2 may be a stronger promoter of genomic instability due to its
expression patterns. Overall, we have identified key differences
between cyclin E1 and E2 in cancer cells that indicate that they are
independently regulated and may be functionally distinct.
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P013-A: A genome-wide association scan
on ER-negative breast cancer
Jingmei Li1,2, Keith Humphreys1, Hatef Darabi1, Gustaf Rosin3,
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Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK,
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of Harvard and Massachusetts Institute of Technology, Cambridge,
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Introduction: Breast cancer is a heterogeneous disease and may be
characterized on the basis of whether estrogen receptors (ER) are
expressed in the tumour cells. ER status of breast cancer is important
clinically, and is used both as a prognostic indicator and treatment
predictor. In this study, we focused on identifying genetic markers
associated with ER-negative breast cancer risk.
Methods: We conducted a genome-wide association analysis of
285,984 SNPs genotyped in 617 ER-negative cases and 4,583 con-
trols. We also conducted a genome-wide pathway analysis on the
discovery dataset using permutation-based tests on pre-defined path-
ways. The extent of shared polygenic variation between ER-negative
and ER-positive breast cancers was assessed by relating risk scores,
derived using ER-positive breast cancer samples, to disease state in
independent, ER-negative breast cancer cases.
Results: Association with ER-negative breast cancer was not
validated for any of the 5 most strongly associated SNPs followed up
in independent studies. However, an excess of small P-values for
SNPs with known regulatory functions in cancer-related pathways
was found (global P = 0.052). We found no evidence to suggest that
ER-negative breast cancer shares a polygenic basis to disease with
ER-positive breast cancer.
Conclusion: ER-negative breast cancer is a distinct breast cancer
subtype that merits independent analyses. Given the clinical impor-
tance of this phenotype and the likelihood that genetic effect sizes are
small, greater sample sizes and further studies are required to
understand the etiology of ER-negative breast cancers.
P014-B: Identification of genes collaborating
with Her2/ErbB2 in mouse mammary tumor
models for human breast cancer
Mandy Boer, Annabel Zwaagstra and John Hilkens
Division of Molecular Genetics, The Netherlands Cancer Institute,
Amsterdam, The Netherlands
MMTV proviral insertion in the genome of murine mammary epithelial
cells can activate flanking proto-oncogenes leading to mammary tumor
induction. We performed an insertional mutagenesis screen in mam-
mary tumors from MMTV-ErbB2 transgenic mice. We identified Eras,
Irs4 and Igf2 as frequent MMTV targets in these mice but rarely genes
acting in the Wnt and Fgf pathways. In contrast, in wild-type mice the
latter genes were the most frequent MMTV targets, whereas the former
genes were only occasionally tagged. Among the three former genes
overexpression of Eras was most significantly associated with ErbB2
positive tumors. ERAS is a constitutive active Ras-like GTPase, nor-
mally only expressed in embryonic stem (ES) cells. It has been reported
that ERAS in ES cells only activates the PI3-kinase but not the MAP-
kinase pathway. Overexpression of both Eras and Irs4 in immortalized
normal mammary epithelial cells (NMuMG cells) strongly increased
the growth rate in vitro, induced anchorage independent growth and
rendered these cells tumorigenic in nude mice, validating the mam-
mary tumor inducing capacity of both genes. Moreover, each of these
genes accelerated ErbB2 induced tumorigenesis when co-expressed in
NMuMG cells. Eras and Irs4 strongly activated the PI3-kinase pathway
in various mammary epithelial cell lines. It has been shown that
ERBB2 in human and mouse mammary tumors forms a heterodimer
with ERBB3. In this complex, ERBB2 mainly activates the MAPK
pathway, while ERBB3 activates the PI3 K pathway. Since ErbB2
driven mammary tumorigenesis is highly dependent on PI3-kinase
activity, we hypothesize that genes like Eras and Irs4 are targeted by
MMTV in ErbB2 tumors that lack ErbB3 mediated PI3 K activation.
Indeed, ErbB3 is highly expressed in all tumors that arise in non-
transfected ErbB2 transgenic mice but only in 60% of the MMTV
infected ErbB2 transgenic mice. Thus activation of the PI3 K-pathway
via Eras, Irs4 and IgF2 can act as an alternative for the activation of this
pathway through ERBB3, PTEN inactivation or PIK3CA mutations.
Eras mRNA was also expressed to a variable degree in a small per-
centage of human breast cancers suggesting a possible involvement of
this normally silent gene in human breast carcinogenesis.
P015-A: Silencing of the PP2A catalytic subunit
causes reduced in PTPase activity that is mediated
via PTP1B in HER-2/neu positive breast cancer
cell lines
Lee Lee Wong1, Chan Fong Chang3 and Evelyn S.C. Koay1,2
1Dept of Pathology and 2Biochemistry, Yong Loo Lin School
of Medicine, National University of Singapore, Singapore,
3Dept of Laboratory Medicine, National University Hospital,
National University Health System, Singapore 119074
The HER-2/neu proto-oncogene has been found to be overexpressed
in 20–30% of breast cancer tumours. This ligandless receptor is able
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to heterodimerize with members of the receptor tyrosine kinase
family and causes autophosphorylation, whereupon signal transduc-
tion events are triggered. Thus, in cancer cells numerous heterodimers
are formed, resulting in unabated aggressive tumour growth and
death. However, relatively little is known of the cellular phospha-
tase(s) responsible for the activation/deactivation of the HER-2/neu
signalling cascade. Protein tyrosine phosphatase 1B (PTP1B) is
required for HER-2/neu transformation in human breast epithelial
cells and inhibition of PTP1B delays HER-2/neu-induced mammary
tumorigenesis. Our group had previously demonstrated that silencing
protein phosphates 2A catalytic subunit (PP2A/C) causes the HER-2/
neu positive breast cancer cells to undergo apoptosis and the PTPase
activity was significantly reduced. Given that PTP1B is required for
HER-2/neu transformation and its association with PP2A is critical
for PP2A activation, we postulated that the decrease in tyrosine
phosphatase activity is contributed by PTP1B. We further silenced the
BT474 and SKBR3 HER-2/neu positive breast cancer cell lines using
siRNA targeting the PP2A/C and examined the effect of silencing
PP2A/C on the expression of PTP1B by Western blotting. Our results
showed that the expression of PTP1B was significantly reduced in
both PP2A/C silenced BT474 and SKBR3 breast cancer cell lines.
Our preliminary study further confirms that the attenuation of PTPase
activity is mediated by PTP1B. However, the association of PTP1B-
PP2A and HER-2/neu is still on-going and remains to be further
elucidated. Our results suggested that silencing of the PP2A/C leads
to reduced tyrosine phosphatase activity that could be mediated by
PTP1B, and thus, contribute to the deceleration of the cell prolifer-
ation and survival rate in HER-2/neu breast cancer cells.
P016-B: Role for JMJD6 in breast cancer
Yi Fang Lee1, Lance D Miller1,2, Kartiki V Desai1
and Edison Liu1
1Genome Institute of Singapore, Agency for Science,
Technology and Research (A*STAR), 2Wake Forest University
School of Medicine
The pathogenesis of breast cancer involves a multitude of genetic
alterations affecting the regulation of cell growth, survival, invasion and
metastasis. To discover such novel oncogenes, we analyzed compre-
hensive gene expression profiles of breast tumors from several breast
cancer patient cohorts for correlations between gene expression and
distant metastasis-free survival. Jumonji Domain Containing 6 Protein
(JMJD6), a histone arginine demethylase was one of the genes associ-
ated with poor survival in all cohorts. Immunohistochemical analysis of
JMJD6 in tissue microarrays suggested that its high expression signif-
icantly correlated with grade and estrogen receptor negativity. In
addition, its over-expression in multiple breast cancer cell lines led to
increased proliferation, while in contrast, siRNA-mediated knock-
down suppressed cell division. Microarray analysis of gene expression
changes induced by siRNA-mediated knock-down of JMJD6 suggested
that JMJD6 led to increased expression of cell cycle genes including
CDC6, CHEK1, and suppression of cell cycle inhibitors like PTEN and
TGF-A˜ZˇAˆ2. We confirmed that siRNA-mediated knock-down of
JMJD6 increased TGF-beta 2 secretion whereas JMJD6 over-expres-
sion reduced it. Since TGF-A˜ZˇAˆ2s have been implicated in cell cycle
arrest in many epithelial cells, we propose that JMJD6 may influence
cell growth primarily via this pathway. Further studies to understand the
molecular relationship between JMJD6 and TGF-A˜ZˇAˆ2 regulation are
underway. These results suggest that the extrapolation of gene-survival
associations in primary tumors to phenotypic analysis in vitro holds
promise as a platform for understanding of new mechanisms in
tumorigenesis, as well as discover new therapeutic targets.
P017-A: BRIP1 and PALB2 mutation detection
in Hunter-New England familial breast cancer cohort
Michelle Wong1, Nikola A. Bowden1, Kelly A. Kiejda1,
and Rodney J. Scott1,2
1Discipline of Medical Genetics and Centre for Information-Based
Medicine (CIBM), The University of Newcastle, Newcastle,
Australia, 2 Division of Genetics, Hunter Area Pathology Service
(HAPS), Newcastle, Australia
Familial breast cancer accounts for 10% of breast cancer cases, and
only 15-20% of these cases arise as a result of mutations in the breast
cancer susceptibility genes, BRCA1 and BRCA2. This remainder of
the cases have not been attributed to any other mutations, and studies
to discover novel breast cancer susceptibility genes have been
unsuccessful. BRIP1 and PALB2 are genes that encode for proteins
that are involved in the BRCA1 DNA damage repair pathway.
Mutations in these genes have been shown to confer an approximately
two-fold increase in the risk of breast cancer compared to population
risks in patients who have Fanconi anemia. However, the incidence of
these mutations in hereditary breast cancer is unknown. The aim of
this study was to determine if BRIP1 and PALB2 mutations are
prevalent in hereditary breast cancer cases that do not have mutations
in BRCA1 and BRCA2. The coding sequences of BRIP1 and PALB2
with exon/intron boundaries were analysed by direct sequencing
methods on genomic DNA of 62 breast cancer patients that are
negative for BRCA1 and BRCA2 mutations. Preliminary results
showed single base changes in BRIP1: 2755T [ C (S919P),
2637A [ G (E879E), and PALB2: 2014G [ C (E672Q), 3114-
51T [ A. The identification of these mutations may enable the
translation of research output to clinical practice by offering genetic
testing of BRIP1 and PALB2 to breast cancer patients referred for
genetic screening.
P018-B: Combined genomic and phenotype screening
to discover novel therapeutic targets in breast cancer
Wendy W. Soon1, Lance D. Miller2, Cyril Dalmasso3,
Kartiki V. Desai1 and Edison T. Liu1
1Department of Cancer Biology and Pharmacology, Genome Institute
of Singapore, Singapore 13867, 2Department of Cancer Biology,
Wake Forest University School of Medicine, Winston-Salem, NC
27157, 3Department of Computational and Mathematical Biology,
Genome Institute of Singapore, Singapore 138672
Secretory factors and extracellular receptors that drive cancer pro-
gression make attractive immunotherapeutic targets. To discover such
novel targetable oncogenes, we used a whole-genome data-mining
approach that takes advantage of large independent microarray
studies of breast tumors annotated for clinical outcomes. Genes
without previous implication in breast cancer were identified based on
their significant association with cancer recurrence in multiple
cohorts, and further filtered for secretory factors and extracellular
receptors based on gene ontology. A high-content screening strategy
was then applied to the candidates to assess the phenotypic conse-
quences of altering candidate gene expression. This screen sug-
gested that serine protease inhibitor Kazal-type 1 (SPINK1), a
secreted extracellular factor, was associated with breast cancer
aggressiveness. We demonstrate that enforced SPINK1 expression
and exposure to exogenous recombinant SPINK1 induce both inva-
siveness and survival of breast cancer cells and down-regulation of
SPINK1 is associated with cancer cell death. Moreover, increased
expression of SPINK1 resulted in an increased resistance to drug-
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induced apoptosis. Immunohistochemical analysis of breast cancer
tissue microarrays suggested that high SPINK1 expression was not
seen in normal breast but is apparent in advanced disease. Moreover,
SPINK1 shows nuclear localization primarily in higher grade breast
cancers. This nuclear localization was recapitulated when tagged
exogenous SPINK1 was applied to cells in vitro. SPINK1 is therefore
a marker for cellular robustness in breast cancer and maybe a
potential therapeutic target in this disease.
P019-A: Radiation induced and telomere associated
genomic instability in breast cancer patients
Birendranath Banerjee1,3, Anuradha Ponepalli1, Sridevi Hedge2
and M Prakash Hande1
1Yong Loo Lin School of Medicine, Department of Physiology,
National University of Singapore, 2Department of Medical Genetics,
Manipal Hospital, Bangalore, India, 3 KIIT School of Biotechnology
(KSBT), KIIT University, Campus-XI, Patia, Bhubaneswar-751024,
Orissa, India
The study was an attempt to correlate the radiation-induced damage in
the peripheral blood lymphocytes (PBLs) of breast cancer patients
with the frequency of telomere mediated chromosomal damage.
Blood samples from 55 patients with (Gr-II and Gr-III) CA-breast
were obtained pre- and post-radiotherapy. The patients were treated
with external beam radiotherapy of 50.4 Gy over a period of 6 weeks.
Chromosome damage was measured by analyzing micronucleus
(MN) frequency in PBLs. The MN-frequency of the irradiated
patients increased significantly compared to the patients being self-
controls. The micronuclei were hybridized with telomere probes to
study the extent of telomere damage. The fluorescence signals of the
telomere regions in the first generation of the bi nucleated cells were
significantly higher in the post-radiotherapy patients.
There was also significant correlation observed in the patients with
higher-grade tumors. Inter-individual variability was observed in the
radiation-induced MN frequency in lymphocytes of patients after
6 weeks of radiotherapy. There was a significant correlation between
functionally intact telomeres and the cellular response to ionizing
radiation. Our findings suggest that fluorescence in situ hybridization
on micronuclei could be effectively used as routine clinical applica-
tion to determine the individual sensitivity to ionizing radiation with
respect to telomere damage.
Sixty-one archived breast tissues (38 cancer tissues and 23 paired
normal tissues) were used in another study. The breast tumor tissues
showed significantly shorter telomeres (7.7 kb) compared with the
paired adjacent tissues (9.0 kb) by Southern blot analysis. Moreover,
telomere shortening was more significant in Grade III tumors than in
the Grade II tumors (P 5 0.05). Quantitative fluorescence in situ
hybridization on paraffin tissue sections revealed a similar trend in
telomere shortening. Telomere attrition was associated with telomere
dysfunction as revealed by the presence of significantly higher ana-
phase bridges in tumor cells which was tumor grade dependent.
Furthermore, estrogen receptive negative tumors displayed higher
anaphase and internuclear bridges. Selected samples from each grade
showed greater genomic imbalances in the higher grades than
the lower grade tumors as detected by array-comparative genomic
hybridization.
Telomerase activity was found to be higher in the higher grades
(Grade II and III) compared with the lower grade (Grade I). The
average mRNA expression of TRF1 and POT1 was lower in the
tumor tissues than in the normal tissues. Tankyrase 1 mRNA
expression showed a grade-dependent increase in tumor tissues and
its expression was also high in estrogen and progesterone negative
tumors. The data support the notion that telomere dysfunction might
be of value as a marker of aggressiveness of the tumors in breast
cancer patients.
P020-B: Loss of Mel-18 enhances the breast cancer stem
cell activity and tumorigenicity through activating
the Notch signaling mediated by the Wnt/TCF pathway
Hee-Young Won1, Jeong-Yeon Lee 2, Dong-Hui Shin1, Ji-Hye Park1,
Tingting Qian1, Hyun-Jun Kim1, Seung-Hyun Oh3,
Jeong-Seok Nam4 and Gu Kong1, 2
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and Biopharmaceutical Research (IBBR), Hanyang University,
Seoul, Republic of Korea, 3Division of Basic and Applied Science,
Korea National Cancer Cencer, Goyang-si, Republic of Korea,
4Laboratory of Tumor Suppressor, Lee Gil Ya Cancer and Diabetes
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Mel-18 has been proposed as a tumor suppressor and negative regulator
of Bmi-1, a cancer stem cell (CSC) marker. However, it is still unclear
whether Mel-18 is involved in CSC regulation. Here, we examined the
role of Mel-18 in the regulation of stemness of human breast CSCs. In
Mel-18 shRNA-transduced MCF7 cells, side population (SP) cells and
breast CSC surface marker (CD44 +/CD24-/ESA +) expressing cells
were enriched. In these cells, the ability for tumorsphere formation and
anchorage independent cell growth were accelerated, indicating the
enhanced self-renewal of CSCs by Mel-18 knockdown. Mel-18
blockade by the shRNA also increased the breast tumor-initiating
capacity in vivo. Using Stem cell PCR array, we found that the
expression of Notch ligand Jagged-1, which is a stem cell specific
marker and target of Wnt/TCF pathway, was upregulated by Mel-18
knockdown. Furthermore, the expression of Notch receptors Notch 1
and 3 were also increased, and nuclear accumulation of cleaved Notch
intracellular domain (NICD) and its target Hes-1 transcription were
consequently upregulated by Mel-18 knockdown. These effects were
blocked by the treatment of b -catenin/TCF inhibitor or Jagged-1
siRNA, indicating Wnt/TCF pathway-mediated Notch activation by
Mel-18 blockade. Pharmacologic inhibition of Notch and Wnt pathway
abrogated the increased tumorsphere formation by Mel-18 downreg-
ulation. Taken together, our findings provide that Mel-18 is a novel
negative regulator of breast CSCs that inhibits stem cell population and
in vitro and in vivo self renewal through the inactivation of CSC self
renewal pathway, Wnt and Notch signaling, suggesting the novel
tumor suppressive role of Mel-18.
P021-A: Constitutive overexpression of Id-1
in mammary glands of transgenic mice results
in precocious and increased formation of terminal
end buds, enhanced alveologenesis, delayed involution
Dong–Hui Shin1*, Si-Hyong Jang1*, Byeong-Cheol Kang2,
Hyun-Jun Kim1, Seung Hyun Oh3 and Gu Kong1,4
1Dept of Pathology, College of Medicine, Hanyang University,
17 Haengdang-dong, Seongdong-gu, Seoul, 133-791, Republic
of Korea, 2Dept of Laboratory Animal Medicine, College
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Inhibitor of differentiation-1 (Id-1) has been shown to play an
essential role in cell proliferation, invasion, migration and anti-
apoptosis. However, the effect of Id-1 in mammary gland develop-
ment remains unknown. Here, we generated MMTV-Id-1 transgenic
mice to study the role of Id-1 in mammary gland development. In
virgin mice, Id-1 overexpression led to precocious development and
delayed regression of terminal end buds (TEBs) compared with wild
type mice. The number of BrdU-positive cells and the expression of
Wnt signaling molecules, b-catenin and cyclin D1, which regulate
ductal extension and TEB formation in virgin, were statistically
higher in Id-1 transgenic mice than in wild type mice. Id-1 also had an
effect on the formation and proliferation of lobuloalveolar structures
during early and midpregnancy. Id-1 transgenic mice had more lob-
ulated and prominent alveolar budding than wild type mice and had
significantly greater counts of lobuloalveolar structures in early
pregnancy. The expression of BrdU, b-catenin and cyclin D1 was also
predominantly increased in Id-1 transgenic mice. Moreover, Id-1
transgenic mice showed delayed involution. Id-1 regulated the
expression levels of anti-apoptotic Bcl-2 and pro-apoptotic Bax, and
resulted in delay of apoptotic peak during postlactational involution.
We also found that Id-1 was able to modulate expression of the
regulators of Wnt/b-catenin signaling such as phospho-Akt, BMP2,
FGF3 and RAR-b in tubuloalveolar development of mammary
glands. Taken together, our results suggestthat Id-1 plays a pivotal
role in mammary gland development through Wnt signaling-mediated
acceleration of precocity and alveologenesis and Bcl-2 family mem-
bers-mediated delay of involution.
P022-B: Using expression profiling to identify
recurrent amplicons
Yu Wing Chee, Kartiki Vasant Desai,
R. Krishna Murthy Karuturi and Edison Liu
Cancer Biology 2; Genome Institute of Singapore, Genome,
60 Biopolis Street, Singapore 138672
Up regulation of transcriptomic dosage usually occurs with amplifi-
cation of genomic loci. In breast cancer, it has been illustrated that
gains of genomic loci result in coordinate expression of the respective
genes. An assessment of this feature, utilizing the combination of
genome wide microarray expression data and patient profiling of 4
different patient cohorts with aggressive breast tumors, we proposed
that recurrent amplicons may exist on 17q12, chr8p11-12, chr11q13
and others. These regions were scored and ranked based on gene
expression levels and frequency across the tumors. Genes that resided
in these amplicons were analyzed for their correlation to poor patient
outcome and were shortlisted as potential candidate oncogenes. In
addition, each of these genes was further analyzed in a pair-wise
manner to determine if co-expression of such pairs improved their
prognostic value. Our results show that the top pair MCM10 and
HOMER3 delivered a prognostic p-value of 6 9 10-13 which is
[6 9 104 times better than the prognostic values the individual
genes. We further validated that the predicted chromosomal aberra-
tions and co-expression of the gene pairs indeed existed in published
primary tumor sequencing and array CGH data. Further analysis to
determine the molecular pathways and mechanisms controlled by
these pairs is underway.
P023-A: Weak genetic factor from Malaysian breast
cancer patients
Salih F1, Mustafa MIA2, Ghazi A2, Samad H3 and Raj GA4
1Department of Biochemistry, Medicine, GMU, 2BMS, Medicine,
International Islamic University Malaysia *, Kuantan, Malaysia,
3Breast Centre, Kulliyyah of Medicine, International Islamic
University Malaysia, Kuantan, Malaysia, 4Department of Pathology,
Medicine, GMU
Introduction: Breast cancer is a common malignancy affecting
women globally. In Malaysia, it constitutes 31% of all newly diag-
nosed female cancer cases. Approximately 50% of the cases occur in
women under the age of 50 years. A proportion of these cases may be
attributable, at least in part, to genetic components. Women who carry
BRCA1 mutations have a probability of about 80% for developing
breast cancer, and 40 to 60% for developing ovarian cancer during
their lifetime. In a previous study by the same authors mutations
(detected by DHPLC using a different primer) were detected in 12.5%
(5/40) of breast cancer patients. Three of them were Chinese, one
Indian and one Malay. In this study the number of patients was
increased to 100. Mutations were detected using PTT technique and
then samples were sequenced. Aim of Study: 1. To investigate and
analyze the role of genetic factor in breast cancer from Malaysian
patients with either early-onset breast cancer (at age B 45 years) or a
positive family history. 2. To test the possible of setting up a
screening and diagnostic test. 3. To explore the possible of devel-
opment drug formulation for treating breast cancer. Materials &
Methods: In collaboration with the IIUM Breast Centre and the
Surgery Department at Hospital Tingku Ampuan Afzan (HTAA),
Kuantan, 100 peripheral blood samples were collected from women
with either early-onset breast cancer or a positive family history of
breast cancer. Mutations were detected in exon 11 of BRCA1 gene by
(Protein Truncation Test (PTT) followed by sequencing. Results: No
truncated protein was detected in any of the 100 samples. Discussion
and Conclusion: In spite of reports in literatures from other countries
documenting evidence of protein truncation mutations in exon11
BRCA1 gene in early onset breast cancer patients, no such mutations
where detected in this study. This may indicate a weak genetic factor
involved in breast cancer from Malaysian patients, or we should look
for mutations in other segments of exon11.
P024-B: Discovery of kinases associated
with acquisition of triple negative phenotype
during antihormonal treatment of ER+ breast
cancer cells
Julia M.W. Gee1, Laura J. Lewis1, Lynne Farrow1,
Richard A. McClelland1 and Robert I. Nicholson1
1Welsh School of Pharmacy, Cardiff University,
King Edward VII Avenue, Cardiff CF103NB, UK
Introduction: Tumours which fail to express ER, PR and lack
amplified HER2 (‘‘triple negative’’ [TN]) comprise *15% breast
cancer de novo with increased risk of early recurrence and poorer
prognosis. As neither antihormones nor trastuzumab are applicable
with only poor responses to EGFR inhibitors (despite *50% TN
disease overexpressing EGFR), such TN tumours are under intense
study to discover treatments, with promising findings for PARP
inhibition. However, a TN state can also be acquired by ER+ breast
cancers during antihormone therapy. 15–40% become ER- on antio-
estrogen relapse, some lacking HER2, while *10% ER + patients
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were ER- (all HER2-) after neoadjuvant letrozole, associating with
aggressive relapse and death. The signalling driving growth of
tumours acquiring a TN state during antihormone treatment remains
unknown. We hypothesise that modelling the acquired TN state and
deciphering its pathways will discriminate future therapeutic targets.
Our objectives were thus to develop experimental models of acquired
TN breast cancer (encompassing EGFR + and EGFR- TN pheno-
types) and to derive gene expression data to discriminate kinases
elevated in this state. Experimental procedures: In vitro cloning,
coupled with immunocytochemical and RT–PCR screening of ER,
PR, HER2 and EGFR status, was used to isolate EGFR+ and EGFR-
TN acquired resistant human breast cancer cell lines following con-
tinuous antioestrogen treatment (10-7 M faslodex) of ER + MCF7
cells. Using triplicate RNA preparations microarrayed with Affyme-
trix HGU133A2.0 GeneChips and median normalising and log-
transforming resultant data, we compared gene expression for the full
kinome (899 probes) between these models, and vs. MCF7. Data
reduction employed t-testing (p \ 0.05) and heatmap profiling using
GeneSifter, applying a[twofold filter to determine kinase expression
altered in each EGFR+ or EGFR- acquired TN phenotype, or
deregulated in all TN models. Differentially-expressed gene lists
underwent Ariadne Pathway Studio ontological analysis. Results: We
cloned 2 novel acquired resistant human breast cancer models,
EGFR+ 22.2 and EGFR- 1.2, which had gained an adverse TN
phenotype during antioestrogen treatment since they lacked HER2,
had lost ER and PR mRNA/protein, showed no antihormone, trast-
uzumab or EGFR inhibitor response, and had increased growth and
invasiveness. 146 kinase genes were deregulated in the TN models.
Along with EGFR, 7 were increased in EGFR+ 22.2 including
receptor tyrosine kinase (RTK) FGFR4, with 27 increased in EGFR-
1.2 including RTKs FGFR2 and MET. 50 further kinases were
increased in both TN lines, including RTKs STYK1 and TYRO3 and
also enrichment of cell cycle/mitosis and DNA repair-associated
kinases. RT–PCR has to date focussed on verifying the RTKs, con-
firming their induced expression profiles in the TN models.
Conclusions: These models comprise a new resource to discover
signalling potentially driving TN tumour phenotypes acquired by
some patients during antihormonal treatment. Significantly, our gene
expression studies have determined that FGFR2, FGFR4, MET,
STYK1 and TYRO3 (RTKs with growth and invasion ontologies) are
worthy of continued investigation to determine if they comprise novel
signalling targets for inhibition of acquired TN breast cancers.
P025-A: Modelling Faslodex response in vitro
to maximise drug effectiveness
H. E. Francies, C. Dutkowski, R. A. McClelland,
L. Farrow, R. I. Nicholson and J. M. W. Gee
Tenovus Centre for Cancer Research, Welsh School of Pharmacy,
Cardiff University, Redwood Building, King Edward VII Avenue,
Cardiff, CF103NB, UK
Introduction: The antihormone tamoxifen and aromatase inhibitors
provide a mainstay in treating early and advanced ER+ breast cancer,
while Faslodex (fulvestrant) is currently approved as a second line
antihormone. However, initial response to antihormones are variable,
complete response is rare, and resistance is eventually acquired by
many patients. It is important to model these events to determine
mechanisms underlying antihormone response and failure so targeted
strategies can be developed to maximise drug effectiveness, but to
date studies have primarily employed MCF7 cells and their deriva-
tives which cannot represent the breadth of ER+ clinical disease.
Focusing on Faslodex, our objective here was to use 4 cell lines in
order to reflect major ER+ clinical phenotypes (ER+/HER2- MCF7,
T47D; ER+/HER2+BT474, MDAMB361) to: (i) characterise in vitro
magnitude of initial response and monitor onset of resistance by
prolonged treatment and (ii) detail gene expression changes during
Faslodex treatment.
Experimental procedures: Cell models were grown in the presence
of Faslodex until resistant sub-populations emerged. In parallel, total
RNA was isolated from untreated and 10 day Faslodex treated cells to
carry out gene microarray analysis using the Affymetrix Human
Genome U133 Array GeneChips. Transcriptome changes were
determined using online and in-house bioinformatic tools including
GeneSifter, and Ariadne Pathway Studio.
Results: All models were initially growth-inhibited by Faslodex,
with superior responses in HER2- lines. In parallel, gene microarray
analysis revealed that while Faslodex both suppressed and induced
genes in all models, its target cohorts generally differed between
HER2+ and HER2- models. Interestingly, while MCF7, BT474 and
MDAMB361 eventually acquired Faslodex resistance, this failed to
develop in T47D providing a model for complete response. Similarly,
the gene cohorts influenced by Faslodex in the complete responding
HER2- T47D line showed further differences both to the HER2-
MCF7 and HER2+ lines, a disparity augmented following treatment.
In order to begin to determine Faslodex-deregulated genes that may
permit subsequent acquisition of resistance, pathway enrichment was
conducted on gene cohorts showing an equivalent expression profile
with Faslodex in BT474, MDAMB361 and MCF7 using Ariadne
software, also filtering for[twofold change with Faslodex, expression
call and adverse ontology. 5 genes emerged as potential cell survival
elements induced by Faslodex in all three models: GRN, PPP3CA,
PRKACB, KITLG and VEGFC. Filtering based on [twofold change
and ontological analysis was also used to determine Faslodex-
deregulated, potential apoptotic or anti-proliferative genes unique
to T47D cells that may facilitate the complete Faslodex response
in this model. 4 genes were identified: DCN, PCDH7, CASP1 and
ADAM12.
Conclusions: Using models spanning ER+ HER2- and
ER+ HER2+ phenotypes, genes have been identified that may permit
cell survival or underlie growth inhibition during Faslodex treatment
of ER + breast cancer and could prove useful predictive biomarkers.
PCR verification and gene knockdown/overexpression studies will
now be performed for the genes of interest to consolidate whether
their signalling comprises novel targets to maximise Faslodex
response.
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To study gene expression regulation and interplay with chromatin
modifications in breast cancer genome we developed set of computer
tools for analysis of ChIP-seq data. Epigenetic modifications are
important in regulation of gene expression. Chromatin landscape and,
in particular, histone H3 modifications, have cell-specific effects on
availability of TF binding sites and recruitment of RNA Pol II
complexes. Recent studies have demonstrated chromatin remodeling
even in terminally differentiated normal cells and advanced-stage
melanoma and breast cancer cells, in context-dependent responses to
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alterations in their microenvironment. Using advances in high
throughput sequencing technologies in combination with chromatin
immunoprecipitation (ChIP-seq), we constructed and analyzed chro-
matin modifications maps in MCF-7 and T47D breast cancer cell lines
for activation marks, H3K4me1, H3K4me3 and H3K27me3 repres-
sive marks. We further analyzed these in conjunction with genome-
wide binding profiles of ER, FOXA1 and p53. Estrogen receptor (ER)
is regarded as a major factor in breast cancer and FoxA1, transcription
factor has been found to function as a pioneer factor in the recruitment
of ER to gene regulatory regions. We used extensive search of co-
motifs in regions proximal to ChIP-seq binding peaks in reference
human genome. Binding motifs of transcription factors AP-1, SP1 and
E2F1 were found among co-activation factors. To show that this was
an unbiased analysis of genome-wide maps we developed software to
test statistical significance of associations between chromatin modi-
fications. The impact of chromatin configuration (as combinations of
histone modification marks) in determining both ER binding site
selection and their association with gene induction or repression by
ER was explored by statistical tools. Predictive logistic regression
model for ERalpha binding was constructed. Clustering of regions
with activating and repressive histone marks in MCF-7 genome
revealed strong co-localization for several histone modifications.
Positive correlation between binding intensity of ERalpha and open
chromatin conformation (activation histone marks) was shown by
statistical measures. In more general approach we studied association
between nucleosome occupancy (predicted by DNA sequence and
experimentally obtained by sequencing) and affinity of TF binding
measured by ChIP-seq. Network analysis of cancer-related genes
within 10 kb of ERalpha binding sites was fulfilled using STRING
protein interaction database, Ingenuity Pathway Analysis (IPA) and
SkyPainter Interactome software. We found clusters of genes having
common chromatin activation pattern. Together, our data shows that
TF binding following gene activation in cancer genome is associated
with chromatin modifications specific for cell lines that could be used
as powerful predictive tool.
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Estrogen receptors (ERs) are ligand-activated transcription factors
that play key roles in many physiological processes and are one of the
most important nuclear hormone receptors in breast cancer biology.
When hormone receptor proteins capture estrogens, the receptors
move to the nucleus and regulate gene expression by binding to
specific DNA sequences known as estrogen response elements (ERE).
Because small changes in nucleotide composition of these DNA
strands can have large effects on transcription rate of target gene, the
ability to detect changes in hormone activity with DNA-level accu-
racy is vitally important.
We have applied two surface plasmon resonance (SPR) techniques
to study ER-ERE interactions, namely planar gold film-based SPR
spectroscopy and gold nanoparticles (AuNPs)-based localized SPR
technique. For the planar gold film-based SPR spectroscopy, we have
designed a series of assay schemes to characterize a wide range of
ER-ERE binding properties, including binding affinity, sequence
specificity, stoichiometry, sequence-independent transient binding,
distinct binding properties of protein subtypes, etc. To facilitate the
high-throughput screening activity, we have developed a simple and
fast AuNPs-based assay to study ER-ERE interactions. The assay is
based on the unique optical properties of AuNPs arising from the
localized SPR phenomenon. ER-ERE binding in homogenous solu-
tions was measured based on interactions with the AuNPs and
modulation of the particlesaˆ€TM optical properties (i.e., LSPR spec-
trum and solution color). The sensitivity of current assay enables
single variations in the ERE core sequences to be colorfully and
instantly detected.
We have benchmarked the AuNPs-based assay to the conventional
planar Au film-based SPR technique. The parallel studies of the same
biological systems using these two techniques allow us to compare
the performance of the solid–liquid phase and homogenous phase
assay modes and to comment on their suitability for fundamental
research and for high throughput screening.
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The onset of both breast and prostate cancers are multi-factorial
events that often depend on steroid signaling pathways downstream of
the estrogen/progesterone/Her2 receptor (breast) and androgen
receptor (prostate). The progression of prostate cancer however, often
involves a molecular switch where the cancer changes from an
androgen dependent tumor to an androgen independent tumor leading
to treatment resistance, while in breast cancer, the largest unmet
medical need lies in the treatment of triple negative (ER/PR/Her2
negative) tumors that are unresponsive to current therapy. This
necessitates the search for novel targets that may be effectively tar-
geted in these hard to treat cancers.
PRMT4 (CARM1) belongs to a family of arginine N-methyl-
transferases enzymes that catalyze the transfer of a methyl group from
S-adenosyl-L-methionine to the side chain nitrogens of arginine res-
idues within proteins to form methylated arginine derivatives and
S-adenosyl-L-homocysteine. Specifically PRMT4 methylates core
histone proteins on H3 and H4, which are also targets of histone
acetylase activity of CBP/p300 coactivators. Recently, PRMT4
epigenetic activity has been implicated in signal transduction, and
transcriptional regulation in the onset and progression of steroid
stimulated breast and prostate cancers. As treatment regimes for
hormonally dependent breast (e.g. Tamoxifene) and prostate (surgical
or chemical castration) cancers already exist, our interest was to
explore if PRMT4 activity played a role in the proliferation of both
hormone dependent and hormone independent breast and prostate
cancers.
Our initial study showed that the transient siRNA knock-down of
PRMT4 expression led to a strong decrease in cell proliferation in
both un-stimulated ER positive (MCF7) and ER negative (MDA-
MB231) breast cancer cells. Follow-up studies in un-stimulated breast
cancer cells utilizing doxycycline inducible, stable lenti-viral vectors
(pSlik) targeting PRMT4 corroborated the strong decrease in cell
proliferation associated with transient (siRNA) PRMT4 knock-down.
Furthermore, knock-down of PRMT4 led to a dramatic decrease in
Histone H3-arginine 2-di-methylation (H3-R2-Me2) mark in the same
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cells, suggesting that the loss of proliferation in breast cancer cells is
associated with the loss of PRMT4 enzymatic activity. In addition, we
showed that inducible knock-down of PRMT4 in 17-estradiol stim-
ulated MCF7 (PRMT4-pSlik) cells led to a significant decrease in
proliferation, confirming previous publications that PRMT4 plays a
role in ER dependent breast cancer proliferation. In addition to breast
cancer, we also showed that knock-down of PRMT4 was associated
with a strong decrease in proliferation in androgen independent
LNCAP prostate cancer cells utilizing the same doxycycline inducible
pSlik system.
This initial data suggests that PRMT4 plays a strong role in the
proliferation of hormone independent breast and prostate cancers. The
development of future therapies targeting PRMT4 may be beneficial
to patients with hormone independent breast and prostate cancers.
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Molecular characterization of the normal epithelial cell types is an
important step towards understanding pathways that regulate self-
renewal, lineage commitment and differentiation along the cellular
hierarchy. In this study we carried out genome-wide mRNA and
microRNA expression profiling in four distinct murine and human
subpopulations: stem cell-enriched, luminal progenitor, mature
luminal and stromal cells. All the mouse mammary epithelial sub-
populations exhibited distinct gene expression and microRNA
signatures, which are substantially conserved with their human
counterparts. The Ingenuity Pathway Analysis (IPA) also identified a
number of conserved pathways across species. This study further
validates the use of the mouse as a model to study mammary gland
development and highlights pathways that are likely to govern cell-
fate decisions and differentiation.
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Background and purpose: Today, breast cancer is one of the most
commonly diagnosed cancers in women. It is well known that dys-
function in the physiological pathways of programmed cell death may
promote proliferation of malignant cells whereas correction of such
defects could selectively induce apoptosis in cancer cells. Sphingo-
lipids, which include ceramides and sphingosine, are essential
structural components of the cell membranes. They have cell mes-
senger function, which regulates cancer cell proliferation, survival
and death. Previous studies have suggested that exogenous and cell-
permeable ceramides may be used as an adjuvant to chemotherapeutic
agents for the treatment of multiple cancers.
Thus, the aim of the present study is to investigate the in vitro
effects of exogenous ceramide on the induction of apoptosis in MCF-
7 cells (breast cancer) as well as to investigate its in vivo effect on a
chemically induced breast cancer model in female Sprague–Dawley
rats.
Method: Mammary carcinogenesis was initiated by a single,
intravenous (i.v.) tail vein injection of 7,12 dimethylbenz(a)anthra-
cene (DMBA) at a dose of 5 mg DMBA/2 ml corn oil/kg body weight
in female Sprague–Dawley rats at 7 weeks of age. Ceramide sup-
plementation was started 5 days in week, 2 weeks prior to DMBA
injection and continued for 24 (31 weeks of animal age) weeks and 35
(42 weeks of animal age) weeks of post DMBA injection. Histopa-
thological, immunohistochemical and morphological studies were
performed such as cell proliferation assay, apoptosis assay, western
blot analysis, TUNEL Assay, annexin V apoptosis Assay, caspase 3-
like activity assay & AKT. Agarose gel electrophoresis was done to
detect the DNA fragmentation. Mitochondrial function was detected
by MTT assay. mRNA expression of Bcl-2 family gene members
were determined by reverse transcription polymerase chain reaction
(RT–PCR).
Results: Ceramide induced apoptosis was observed in MCF-7 cells
at 0, 8, 16, and 24 h, and the cell viability was detected & cell
counting was analyzed using ELISA. After exposure to 20 lmol/L of
C6-ceramide for 8 and 24 h, cell apoptosis was found to be 54.1% and
85.3% respectively. This showed a time and dose-dependent rela-
tionship. The detection of apoptosis was done by fluorescein
isothiocyanate labeled annexin V followed by flow cytometric anal-
ysis of the apoptotic cells. After C6 ceramide treatment, typical
characteristics of apoptosis, such as nuclear chromatin breakage,
apoptotic body and DNA ladder, could be observed. Meanwhile,
ceramide up-regulated or down-regulated the mRNA expression of
Bcl-2 family gene members with reduced antiapoptotic phosphory-
lation of the Akt. Administration of ceramide further showed a
prominent reduction of cell proliferation (27.44%, P \ 0.001) and an
increased expression of p53 protein (3.34 ± 0.11, P \ 0.001) in
preneoplastic mammary tissue when compared to carcinogen control
counterpart. Histopathological and morphological analyses were
carried out as end-point biomarkers.
Conclusion: This study shows that C6-ceramide may have
potential anti-carcinogenic effect in both in vitro and in vivo mam-
mary carcinoma by affecting cellular proliferation and apoptosis.
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The Hh signalling pathway plays an important role in a number of
malignancies, and accumulating evidence suggest it contributes to the
development and progression of breast cancer. However, there is
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relatively scant data regarding the clinical significance of Hh pathway
dysregulation in breast cancer or its contribution to malignancy in
vivo. We investigated the expression of Hh pathway components in a
well-characterised cohort of 279 patients with invasive ductal carci-
noma (IDC) to determine its prognostic significance and found high
Hh ligand expression was associated with increased risk of breast
cancer recurrence (HR 1.95, p = 0.0004) and breast cancer specific
death (HR2.3, p = 0.0002). High Hh was also strongly associated
with the basal-like phenotype. Furthermore high Hh expression is an
early event in the development of breast cancer, and was observed in
two independent histological progression series (n = 301) to increase
with greater atypia and malignancy of pre-invasive lesions. Hh ligand
overexpression in a mouse mammary carcinoma model resulted in a
fourfold increase in tumor size, and was associated with increased
proliferation, shorter time to metastases and shorter survival times
(p = 0.0001).
Furthermore, tumors overexpressing Hh were histologically more
poorly differentiated than control tumors. Hh overexpression in vivo
was associated with robust upregulation of canonical Hh target genes
Ptc2, Gli1 and HHip. Cellular fractionation of tumours revealed that
gene expression was activated in stromal cells, rather than the neo-
plastic cells, indicated a paracrine mechanism for Hh action.
To determine whether Hh is a potential therapeutic target for
breast cancer, we treated tumor-bearing mice with the Hh neutralizing
monoclonal antibody 5E1. Inhibition of Hh signaling caused a dra-
matic reduction in tumour growth rate and metastatic dissemination
compared to mice treated with control antibody. Using an aggressive
metastatic mammary carcinoma cell line model (4T1) that endoge-
nously expresses Hh ligand, treatment with antibody 5E1 also resulted
in reduced lung metastatic burden (p = 0.045).
In conclusion, we report that high Hh ligand is associated with a
poor prognosis in IDC and is an early event in breast cancer devel-
opment. Overexpression of Hh ligand promotes mouse mammary
tumor growth as well as shorter time to metastatic disease and death,
via paracrine signalling to adjacent stroma. Finally, we demonstrate
that blockade of the Hh ligand is a potential therapy in metastatic
breast carcinoma. These data are all unpublished.
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Despite binding to near-identical DNA sequences with high affinity,
individual Sox proteins regulate the expression of distinct sets of
genes leading to diverse cell fate decisions. Importantly, Sox proteins
bend DNA by interacting with the minor groove of the double-helix.
DNA bending may be a crucial act to assemble specific regulatory
complexes and different bending angles may result in variant tran-
scriptional outcomes. Here we asked whether individual Sox family
members deform DNA in a distinctive manner to facilitate the sub-
sequent formation of Sox-specific regulatory complexes. To this end
we measured the FRET efficiency of fluorescently labeled DNA
before and after protein addition. After determining the distances of
the DNA ends we were able to compare bending angles induced by
Sox2, Sox4, Sox5, Sox7, Sox17 and Nanog at saturating concentra-
tions. We found that all Sox proteins significantly shorten end-to-end
distances consistent with a bending angle of *708, but the homeo-
domain protein Nanog showed no bending effects. Notably, while the
other Sox proteins deformed DNA in an indistinguishable manner,
Sox 5 was found to bend DNA significantly less strongly. Further-
more the influence of cation concentrations and variations in the DNA
sequence on the bending angle was investigated. We conclude that
even though differential bending does not suffice to explain the
multitude of biological processes regulated by Sox proteins subtle
differences as seen for Sox5 may contribute to its specific biological
role.
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Estrogen receptor (ER) is important in the development and pro-
gression of breast cancer. Using ChIP-sequencing, we mapped the
genomic landscape of ERa binding sites (ERBS) in the breast cancer
cell line, MCF-7. To understand what factors can influence the
transcriptional activity of ERa, we performed cofactor motif analysis
on the ERa binding sites identified by ChIP-sequencing. Our analysis
revealed the binding sequences of AP2 family of transcription factors
were highly enriched in the ERBS. The AP2 family of transcription
factors is known to orchestrate a variety of cellular processes,
including cell growth, cell adhesion and tissue differentiation. AP2c, a
member of the AP2 family, has been shown to be over-expressed in
breast tumors, however little is known on how it regulates tran-
scription in breast cancer. Here, we showed that AP2c is recruited to
the distal ERBS of the estrogen regulated gene, rearranged during
transfection (RET), in a ligand-independent manner. Using a com-
bination of siRNA, ChIP and Chromosome conformation capture (3C)
assays, we showed that AP2c is essential for the recruitment of ERa
and FoxA1, and the long-range chromatin interaction at the RET
gene. Moreover, down-regulation of AP2c resulted in reduced RET
transcription. Taken together, our data suggests that multiple tran-
scription factors (e.g. AP2c and FoxA1) are pre-loaded at ERBS
establishing functional complexes of cofactors that are required for
the coordinated regulation of ERa activity.
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